The 6 most recent market catalysts affecting $EVMN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 23, 2026
Corporate Catalyst
Neutral
Impact 65
Evommune To Present Results From Phase 2a Study Of EVO301 In Moderate-To-Severe Atopic Dermatitis At European Academy Of Dermatology & Venereology Congress
Evommune, a clinical-stage biotechnology company, has announced that it will present Phase 2a trial results for its drug candidate, EVO301, at a major medical conference in 2026. T…
Sep 9, 2026
Corporate Catalyst
Bearish
Impact 55
Leerink Partners Maintains Outperform on Evommune, Lowers Price Target to $22
Leerink Partners maintaining an 'Outperform' rating suggests a continued belief in Evommune's fundamental strength and future growth potential. However, the reduction in the price …
Sep 9, 2026
Corporate Catalyst
Bearish
Impact 65
RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $21
RBC Capital's analyst Brian Abrahams maintained an 'Outperform' rating on Evommune, signaling continued confidence in the company's fundamentals or future potential. However, the s…
Sep 9, 2026
Corporate Catalyst
Bearish
Impact 85
Evommune Halts Atopic Dermatitis Program Following Trial Failure
Evommune's EVO756 failed to meet primary and secondary endpoints in its Phase 2b trial for atopic dermatitis, leading the company to halt development for this indication. This is a…
Aug 26, 2026
Corporate Catalyst
Neutral
Impact 65
Needham Initiates Coverage On Evommune with Buy Rating, Announces Price Target of $28
Needham analyst Serge Belanger has initiated coverage on Evommune (EVMN) with a 'Buy' rating and a $28 price target. This event is significant for EVMN as it introduces a new insti…
Aug 7, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $29
RBC Capital analyst Brian Abrahams maintained an 'Outperform' rating on Evommune, signaling continued confidence in the company's fundamentals and future performance. However, the …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.